Sequel Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 20-06-2024
- Paid Up Capital ₹ 5.80 Cr
as on 20-06-2024
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 20-06-2024
- Satisfied Charges ₹ 36.09 Cr
as on 20-06-2024
- Revenue %
(FY 2020)
- Profit 93.21%
(FY 2020)
- Ebitda 93.28%
(FY 2020)
- Net Worth -0.02%
(FY 2020)
- Total Assets -0.30%
(FY 2020)
About Sequel Pharmaceuticals (India)
The Corporate was formerly known as Sequel Pharmachem Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.80 Cr.
The company currently has active open charges totaling ₹5.00 Cr. The company has closed loans amounting to ₹36.09 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nandadip Rasam and Ramchandra Parade serve as directors at the Company.
- CIN/LLPIN
U24239MH2006PTC162896
- Company No.
162896
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jun 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Ambernath, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sequel Pharmaceuticals (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nandadip Rasam  | Director | 06-May-2023 | Current |
| Ramchandra Parade | Director | 18-Jun-2020 | Current |
Financial Performance of Sequel Pharmaceuticals (India).
Sequel Pharmaceuticals (India) Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 93.21% increase in profit. The company's net worth dipped by a decrease of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sequel Pharmaceuticals (India)?
In 2018, Sequel Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Nkgsb Co-Op. Bank Ltd. Creation Date: 07 Apr 2011 | ₹5.00 Cr | Open |
Corporation Bank Creation Date: 22 Dec 2007 | ₹29.31 Cr | Satisfied |
Janakalyan Sahakari Bank Ltd. Creation Date: 10 Aug 2007 | ₹4.18 Cr | Satisfied |
How Many Employees Work at Sequel Pharmaceuticals (India)?
Unlock and access historical data on people associated with Sequel Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sequel Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sequel Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
